The company was established at No. 2 Tianjiaqiao, Tiyuchang Road, Hangzhou.
The company advanced the pre-clinical research of icotinib hydrochloride.
The company’s staff celebrated the completion of the pre-clinical studies of icotinib hydrochloride.
The company moved to Yuhang Economic and Technological Development Zone and established a manufacturing site.
Icotinib hydrochloride won the supports from the National Torch Program and the National Science and Technology SME Technology Innovation Fund.
Beijing R&D Center was moved for the first time.
Icotinib hydrochloride received the support from the National 863 Program.
Beijing R&D Center celebrated its fifth anniversary.
The company was recognized as a national high-tech enterprise for the first time.
The company held the groundbreaking ceremony of its headquarter in Hangzhou.
Icotinib hydrochloride won the special project support of National "New Drug Innovation".
Manufacturing of icotinib hydrochloride was successfully scaled up in 1,000 liters.
The clinical study of icotinib hydrochloride was completed clinical research and the industrial manufacturing was initiated.
The marketing launch of icotinib hydrochloride results was held in the Great Hall of the People in Beijing and was hailed as a significant milestone in the Chinese healthcare industry.
Betta Pharmaceuticals academician site was established.
The company cooperated with the China Pharmaceutical Promotion Association to launch the Conmana patient assistance program.
Icotinib hydrochloride was listed in the 2012 Global New Drug R&D Catalogue as the first Chinese innovative drug to be enlisted.
The company and Amgen established a joint venture.
The results of the clinical study of icotinib hydrochloride were published in The Lancet Oncology.
The company signed a contract with Xcovery to jointly develop a new generation of ALK inhibitor ensartinib hydrochloride.
Construction of a new headquarter site was initiated.
R&D and commercialization of icotinib hydrochloride won the first prize of 2015 National Scientific and Technological Progress Award.
The company was appraised as China Overseas Chinese Innovation and Entrepreneurship Site.
Betta Pharmaceuticals was listed on the Shenzhen Stock Exchange (300558.SZ).
Icotinib hydrochloride won China Industrial Award.
The Chinese Academy of Pharmaceutical Innovation and Industrialization Forum was successfully held at the company's new headquarter.
Betta DreamWorks was officially established
Icotinib hydrochloride was listed on the National Reimbursement Drug List (NRDL).
The company reached a strategic collaboration with Tyrogenex.
Haichuang Park of Betta DreamWorks was officially opened.
Icotinib hydrochloride was listed on the Essential Drug List (EDL).
The NDA application of ensartinib hydrochloride was accepted by the National Medical Products Administration (NMPA).
Ensartinib hydrochloride was granted the priority review by the Center for Drug Evaluation of NMPA.
The clinical results of ensartinib hydrochloride were published in The Lancet Respiratory Medicine.
Icotinib hydrochloride was included in the General Drug Access Catalogue of National Medical Insurance (2019).
The company's first macromolecule biologics product, Bevacizumab, was approved
Icotinib was approved as postoperative adjuvant therapy for NSCLC.
Icotinib postoperative adjuvant therapy and Ensartinib were includedthe catalog of medicines covered by national medical insurance system
In 2022, CDE approved 4 new indications for Bevacizumab
Ensartinib Hydrochloride was presented at the CCP’s 20th exhibition on the theme of "Forging Ahead in the New Era"
Befotertinib Mesylate and Vorolanib were approved for marketing
Four products were included the catalog of medicines covered by national medical insurance system